It’s been more than ten years since the FDA signed off on the United States’ first biosimilar product, opening up what was ...

USD 100 million senior term loan facility with a 2-year maturityStrengthens liquidity to support execution across Alvotech’s R&D pipeline and ...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 ...

The transition process will begin immediately, with Ms Graver working closely with Mr Wessman and the executive team over the ...

NICE has backed NHS use of natalizumab, a key treatment option that is safe for use in pregnancy, for more patients with ...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support Teva's anti-IL-15 candidate TEV-'408TEV-' ...

The Skinny Labels, Big Savings Act was introduced on January 9 in an effort to provide “a statutory safe harbor from patent ...

The ever-shifting political landscape in the United States has made advocacy a critical component — and challenge — for every professional medical organization, including those in rheumatology. The ...

Discover the top 3 undervalued Health Care Providers & Services stocks for Thursday, January 01 based on AAII’s Stock Grades.

Learn about the benefits that become permanent features of Medicare in 2026 and how they have been changed or updated since ...

Looking for a potential ten-bagger in the gold sector? Analysts believe this could be possible for Desert Gold. The recently ...

As drug pricing pressure intensifies and benefit structures shift, some health systems are still treating biosimilars as a selective cost lever — deploying them in certain payer segments while ...